Molecular structure of tuberculosis efflux pump reveals how bacteria resist key antibiotic by Jeff Hansen, University of Alabama at Birmingham edited by Sadie Harley, reviewed by Robert Egan ...

The structure showed 12 transmembrane helices in two pseudo-symmetric bundles and two periplasmic subdomains. Experiments showed that the coiled-coil domain, whose predicted model extends from one of ...

In particular, Inclisiran, an siRNA agent against PCSK9, and the monoclonal antibodies such as evolocumab and alirocumab stand out.

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass ...

Researchers reveal unprecedented insights into insulin resistance that could pave the way for better treatments and earlier detection of type 2 diabetes.

Phase 2 peri-operative study of fianlimab + cemiplimab + chemotherapy versus cemiplimab + chemotherapy in resectable early-stage non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract ...

Food contains more than 139,000 molecules, which influence nearly half the human proteome. Systematic analysis of food–chemical interactions can potentially advance nutrition science and drug ...

Although untargeted mass spectrometry-based metabolomics is crucial for understanding life’s molecular underpinnings, its effectiveness is hampered by low annotation rates of the generated tandem mass ...

The LIBerate-HoFH study assessed the safety and efficacy of monthly lerodalcibep and evolocumab in a randomized, cross-over trial, with 24 weeks of treatment in each period separated by a washout ...

WASHINGTON — Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab than methotrexate, according to data presented at ACR Convergence ...

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).